Navigation Links
Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
Date:10/23/2007

CALGARY, Oct. 24 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that a poster presentation covering interim results from a U.K. Phase Ia/Ib combination REOLYSIN(R)/radiation clinical trial for patients with advanced or metastatic cancers is scheduled to be presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco. The conference runs from October 22-26, 2007.

"We are very encouraged with the results of this trial to date," said Dr. Brad Thompson, President and CEO of Oncolytics. "The data is supportive of our ongoing Phase II REOLYSIN(R)/radiation cotherapy trial in the U.K."

The interim results of the Ia/Ib trial demonstrate that intratumoural treatment with REOLYSIN(R) and radiation is well tolerated and results in both local and remote anti-tumour activity in patients with a variety of advanced cancers. Oncolytics continues to enroll patients in the Ib portion of this trial, and is also actively enrolling patients in a Phase II trial examining this treatment combination.

The presentation, entitled "A Phase I study to evaluate the feasibility, safety and biological effects of intratumoural administration of wild-type Reovirus (REOLYSIN(R)) in combination with radiation in patients with advanced malignancies" will be delivered by Dr. Dean Harris of The Institute of Cancer Research, London.

These interim results were also presented in early October at the National Cancer Research Institute (NCRI) Cancer Conference in Birmingham, U.K.

The poster presentation will be posted on the Oncolytics website today at http://www.oncolyticsbiotech.com.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the six months ended June ... in Canadian dollars and presented under International Financial ... Highlights , Announced top-line results related ... endpoint for subjects enrolled in the Phase 2 ...
(Date:8/29/2014)... Due to a misstatement posted by the Family ... Technology Center, LLC ( ASCTC ) was reported as an ... might benefit ALS patients. Because of ASCTC's exclusive focus ... and therapeutic applications, FRC listed ASCTC as one of several ... wish not to support research that requires the death of ...
(Date:8/28/2014)... USA (PRWEB) August 28, 2014 SPIE ... of Physics and Optical Science and Director of the ... of North Carolina at Charlotte, and co-founder and Chairman ... to serve as the 2015 Vice President of SPIE, ... 2014 President Philip Stahl announced recent election results at ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 “This kit has ... to screen from 0 to 150 ppb,” said Mark Tess, ... a significant benefit to plant owners and USDA-GIPSA inspection agencies ... other commodities. Testing can take place in a matter of ... can the plant test the feed and grain before accepting ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2
... present itself as one of the,world,s leading regenerative ... Under the "Breakthroughs in Regenerative Medicines,in Germany" banner, ... research results in the area of regenerative medicine ... framework conditions will be,introduced in a presentation in ...
... genetics,(Nasdaq: DCGN ) today announced that ... processes the company,s deCODEme(TM) personal,genome scans and ... has been accredited by the American College ... U.S. Centers for Medicare and Medicaid,Services (CMS) ...
... /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine ... the National Research Council Institute for Biodiagnostics (NRC-IBD) ... technology to track the effect of IVT,s DepoVax(TM) ... has the potential to deliver extremely sensitive MRI ...
Cached Biology Technology:BIO International Convention 2009: Research Location Germany Presents Potential in Regenerative Medicine 2deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 2deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 3deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation 4ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imagin 2
(Date:8/28/2014)... researcher and his collaborators have developed an online analytic ... of re-engineering cells for biomedical investigation. CellNet is a ... aid stem cell engineering. Details of CellNet and its ... back-to-back papers in the journal Cell . , ... for all types of cell-based investigations and can potentially ...
(Date:8/28/2014)... the developmental on-off switch for Streptomyces , a ... of the world,s naturally derived antibiotic medicines. , ... is possible to manipulate this switch to make nature,s ... August 28 in Cell , found that a ... a larger protein called BldD ultimately controls whether a ...
(Date:8/28/2014)... systems are good examples of complex systems. Their ... networkincluding water for cooling, transport to supply fuel, ... step in the network chain is interconnected with ... dependent. A team of UK-based scientists has studied ... The findings have been published in EPJ B ...
Breaking Biology News(10 mins):New tool aids stem cell engineering for medical research 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3Inter-dependent networks stress test 2
... recognition of her ongoing support of the nation,s human ... 2012 recipient of the National Space Biomedical Research Institute,s ... was honored today during the official opening of a ... Baylor College of Medicine,s Center for Space Medicine (CSM). ...
... Wildlife Conservation Society, the ARC Centre for Excellence ... more than 40 coral reefs in the Indian ... between local communities, conservation groups, and governmentsprovides one ... The finding is the outcome of the largest ...
... ColdQuanta Inc. of Boulder and the University of Colorado ... physics research developed by CU-Boulder and SRI International. The ... new form of matter created just above absolute zero. ... be used to dramatically increase the performance of devices ...
Cached Biology News:Space research institute honors Sen. Hutchison with Pioneer Award 21 solution to global overfishing found 21 solution to global overfishing found 3Ultracold matter technology from CU and SRI International licensed to Boulder's ColdQuanta 2
... The iCycler thermal cycler with 384-well ... amplification (PCR) applications. It is equipped with ... samples) and features algorithm temperature monitoring and ... for small sample volumes. It includes the ...
... systems, known as ChemiArrayTM Mouse Cytokine ... with current methodologies. Besides the ability ... present a more accurate reflection of ... detect secreted cytokines, and no amplification ...
Request Info...
Request Info...
Biology Products: